The Journal of Practical Medicine >
A randomized controlled study of doubling the first dose of batroxobin in the treatment of total frequency descending sudden deafness
Received date: 2025-03-28
Online published: 2025-07-18
Objective To explore the therapeutic effect of doubling the first dose of batroxobin in the treatment of sudden sensorineural hearing loss with reduced frequency. Methods A total of 96 patients diagnosed with sudden sensorineural hearing loss， who received treatment at the Department of Otolaryngology at the Second Affiliated Hospital of Guizhou Medical University between August 2022 and October 2024， were included in the study. Using the random number table method， the patients were assigned to two groups， an observation group and a control group， each comprising 48 cases. The control group was treated with Ginkgo biloba extract， methylprednisolone tablets， and a first dose of 10 BU of batroxobin， while the observation group was treated with Ginkgo biloba extract， methylprednisolone tablets， and a first dose of 20 BU of batroxobin. After one cycle of treatment， compare the pure tone hearing threshold， hemorheological indicators， coagulation function indicators， efficacy， and adverse reactions between the two groups. Follow up for 6 months and record the recurrence outcome. Results After treatment， the pure tone hearing threshold of both groups decreased， and the observation group was lower than the control group （P < 0.05）. After treatment， the effective rates of the observation group and the control group were 77.08% and 54.17%， respectively， and the whole blood low shear viscosity was （18.27 ± 1.63） （20.29 ± 1.41） mPa·s， the whole blood shear viscosity was （5.58 ± 0.64）， （6.01 ± 0.69） mPa·s， the whole blood high shear viscosity is （4.26 ± 0.38）， （4.54 ± 0.31） mPa·s， the plasma viscosity is （1.52 ± 0.26）， （1.71 ± 0.34） mPa·s， the red blood cell aggregation index is （0.60 ± 0.21）， （0.52 ± 0.17）， the red blood cell deformation index was （5.73 ± 0.61）， （6.20 ± 0.64）， and the fibrinogen （FIB） is （0.72 ± 0.18）. 0.95 ± 0.13） g/L， thrombin time （TT） were （23.51 ± 2.08） and （21.76 ± 2.13） s， prothrombin time （PT） were （12.71 ± 0.63） and （12.05 ± 0.65） s， respectively， and activated partial thromboplastin time （APTT） were （28.32 ± 3.07） and （29.51 ± 2.24） s， respectively， with the observation group showing more significant changes （P < 0.05）. The recurrence rate of the observation group was lower than that of the control group （P < 0.05）. Conclusion Doubling the first dose of batroxobin can help alleviate the symptoms of hearing impairment， improve inner ear microcirculation， and enhance treatment efficacy in patients with total frequency decline type sudden deafness.
Qin YANG , Xuejie WANG , Kefu ZHAI . A randomized controlled study of doubling the first dose of batroxobin in the treatment of total frequency descending sudden deafness[J]. The Journal of Practical Medicine, 2025 , 41(13) : 2082 -2087 . DOI: 10.3969/j.issn.1006-5725.2025.13.020
| [1] | CHRYSOULI K， KOLLIA P， PAPANIKOLAOU V， et al. The effectiveness of intratympanic steroid injection in addition to systemic corticosteroids in the treatment of idiopathic sudden sensorineural hearing loss［J］. Am J Otolaryngol，2023，44（4）：103872. doi:10.1016/j.amjoto.2023.103872 |
| [2] | 朱红美，黄永久，储九圣，等. 中性粒细胞/淋巴细胞比率和单核/高密度脂蛋白胆固醇比率在突发性耳聋患者中的表达水平及与预后的相关性［J］. 实用医学杂志，2024，40（24）：3503-3508. |
| [3] | 中华耳鼻咽喉头颈外科杂志编辑委员会，中华医学会耳鼻咽喉头颈外科学分会. 突发性聋诊断和治疗指南（2015）［J］. 中华耳鼻咽喉头颈外科杂志，2015，50（6）：443-447. |
| [4] | LEE J K， YOON C S， NA Y O， et al. Risk factors and clinical outcomes associated with acquired hypofibrinogenemia in patients administered hemocoagulase batroxobin for hemoptysis［J］. J Thorac Dis，2023，15（1）：65-76. doi:10.21037/jtd-22-717 |
| [5] | JIANG L Z， ZUO W Q. Batroxobin can improve the efficacy of combination therapy for profound sudden sensorineural hearing loss greater than but not less than 100 dB HL［J］. J Laryngol Otol，2024，138（3）：270-275. doi:10.1017/s0022215123001512 |
| [6] | 孟德静，李艮平，吴晓平，等. 巴曲酶治疗全频下降型突发性耳聋的疗效观察及与凝血功能的相关性分析［J］. 中国耳鼻咽喉颅底外科杂志，2022，28（6）：44-47. |
| [7] | GARCIA-RODRIGUEZ E A， MANCILLA-MEJIA F J， DIRZO-CUEVAS S L， et al. Hearing results with combination steroid therapy for sudden sensorineural hearing loss［J］. Cir Cir，2023，91（6）：816-823. doi:10.24875/cirue.m22000712 |
| [8] | CHAVKIN U， PITARO J， GAVRIEL H， et al. The impact of eustachian tube function on intra-tympanic steroid administration［J］. Eur Arch Otorhinolaryngol，2023，280（1）：143-149. doi:10.1007/s00405-022-07475-8 |
| [9] | MIRSALEHI M， GHAJARZADEH M， FARHADI M， et al. Intratympanic corticosteroid injection as a first-line treatment of the patients with idiopathic sudden sensorineural hearing loss compared to systemic steroid： A systematic review and meta-analysis［J］. Am J Otolaryngol，2022，43（5）：103505. doi:10.1016/j.amjoto.2022.103505 |
| [10] | DENG H S， HOU Y W， ZHANG J N， et al. Postauricular versus systemic use of steroids for sudden hearing loss： A systematic review and meta-analysis of randomized controlled trials［J］. Medicine （Baltimore），2023，102（32）：e34494. doi:10.1097/md.0000000000034494 |
| [11] | LEE J W， KIM H， KONG S K， et al. The Effectiveness of Salvage Hyperbaric Oxygen Therapy Following Combined Steroid Therapy for Refractory Sudden Sensorineural Hearing Loss［J］. Ann Otol Rhinol Laryngol，2024，133（4）：400-405. doi:10.1177/00034894231222692 |
| [12] | KOVACS M， UZSALY J， BODZAI G， et al. Efficacy of high dose systemic versus combined （systemic and intratympanic） corticosteroid therapy in idiopathic sudden sensorineural hearing loss： A prospective randomized trial and risk factor analysis［J］. Am J Otolaryngol，2024，45（1）：104099. doi:10.1016/j.amjoto.2023.104099 |
| [13] | 吴君，顾晓峰. 乌灵胶囊联合胞磷胆碱钠胶囊治疗老年突发性耳聋［J］. 实用医学杂志，2024，40（21）：3090-3094. |
| [14] | LE X， LIU J， JIA Q， et al. Effect of combining batroxobin with acupuncture treatment on hearing recovery in patients with sudden sensorineural hearing loss［J］. Acta Otolaryngol，2024，144（4）：299-305. doi:10.1080/00016489.2024.2369295 |
| [15] | ZHOU W， YUAN H， YANG Y， et al. Nomogram for predicting the prognostic role in idiopathic sudden sensorineural hearing loss［J］. Am J Otolaryngol，2023，44（2）：103736. doi:10.1016/j.amjoto.2022.103736 |
| [16] | 刘佳荣，张莉，段宏. 大剂量糖皮质激素冲击疗法对单侧全聋型突发性聋患者的临床疗效观察［J］. 北京医学，2024，46（2）：103-106. |
| [17] | BALAI E， GUPTA K K， DARR A， et al. Comparing the use of high dose to standard dose corticosteroids for the treatment of sudden sensorineural hearing loss in adults - A systematic review［J］. Auris Nasus Larynx，2024，51（1）：11-24. doi:10.1016/j.anl.2023.04.008 |
| [18] | 张鑫婷，王占山，黄东辉. 巴曲酶联合针刺疗法治疗难治性突发性耳聋的临床疗效［J］. 广东医学，2024，45（12）：1617-1620. |
| [19] | 吕嘉雯，黄浦城，马淑婷，等. 甲泼尼龙琥珀酸钠联合巴曲酶治疗突发性耳聋的临床研究［J］. 中国药物应用与监测，2024，21（5）：652-655. |
| [20] | KUO L K， WU J L， LI Y L， et al. Clinical efficacy of intratympanic steroid injection for treating idiopathic sudden sensorineural hearing loss［J］. J Chin Med Assoc，2024，87（3）：328-333. doi:10.1097/jcma.0000000000001061 |
| [21] | PLONTKE S K. The HODOKORT trial and current aspects of treatment of idiopathic sudden sensorineural hearing loss with glucocorticoids［J］. HNO，2024，72（6）：389-392. doi:10.1007/s00106-024-01458-3 |
| [22] | WANG B， ZHANG W， ZHANG J， et al. Efficacy and fibrinogen correlations of defibrinogen therapy in idiopathic sudden sensorineural hearing loss［J］. Sci Rep，2025，15（1）：4311. doi:10.1038/s41598-024-84723-3 |
| [23] | ZHU Y， HE S， LIAO K， et al. Clinical Profiles and Prognoses of Adult Patients with Full-Frequency Sudden Sensorineural Hearing Loss in Combination Therapy［J］. J Clin Med，2023，12（4）：1478. doi:10.3390/jcm12041478 |
| [24] | 张娟，张燕，段雪梅，等. 高压氧联合灵骨穴深刺治疗突发性耳聋的疗效及对患者血液流变学指标的影响［J］. 保健医学研究与实践，2023，20（3）：141-144. |
| [25] | 张梦君，戴嵩，唱得龙. 补体C3、C4、抗凝蛋白及血液流变学与突发性耳聋发病及预后相关性分析［J］. 中华耳科学杂志，2022，20（4）：554-559. |
| [26] | 董铭杰，薛瑞君，王平，等. 高压氧舱内同步脑仿生电刺激治疗突发性耳聋的疗效及血液流变学变化［J］. 中华航海医学与高气压医学杂志，2022，29（1）：61-64. |
| [27] | 马永驰，朱文燕，金新. 甲泼尼龙耳后局部注射对低频下降型突发性聋的效果及血液流变学和安全性的影响［J］. 中国医药导报，2023，20（3）：97-99，103. |
| [28] | DONG H， LIU M， RONG L， et al. Efficacy and Hemorheology of Ginkgo biloba Extract （EGb 761） in the Treatment of Sudden Sensorineural Hearing Loss： A Retrospective Study［J］. Noise Health，2024，26（122）：383-389. doi:10.4103/nah.nah_73_24 |
| [29] | FENG T， ZHANG Q， WEI J， et al. Effects of alprostadil combined with hyperbaric oxygen on hearing recovery and hemorheology in patients with sudden sensorineural hearing loss and analysis of related influencing factors［J］. Exp Ther Med，2022，23（3）：242. doi:10.3892/etm.2022.11167 |
| [30] | YUAN C， ZHANG H， SUN C， et al. Efficacy and safety of Ginkgo biloba extract as an adjuvant in the treatment of Chinese patients with sudden hearing loss： A meta-analysis［J］. Pharm Biol，2023，61（1）：610-620. doi:10.1080/13880209.2023.2190782 |
/
| 〈 |
|
〉 |